Bayer Chief Executive, Marijn Dekkers, talks with Pharma Times on outcomes-based pricing, but goes on to describe some of the problems with pharmaceutical patenting. What if the automotive industry had patents like the pharmaceutical industry? Read more here. (Source: Kevin Grogan, PharmaTimes digital, 12/3/14)
You are here: / / How Does Bayer CEO Feel About Outcomes-Based Pricing?